HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sunscreen SPF Cap Would Reduce User Protection, Manufacturers Say

This article was originally published in The Rose Sheet

Executive Summary

FDA’s proposal to cap SPF claims at 50 could undermine public health rather than enhance it, sunscreen marketers maintain.

You may also be interested in...



PCPC, EWG Reps Wrangle Over Sunscreen SPF Cap At Expo West

The Personal Care Products Council and Environmental Working Group do not see eye to eye on FDA’s proposed SPF cap, as was made clear at Natural Products Expo West where attorneys from the groups presented in a session on natural sunscreen.

P&G Backs Proposed SPF Cap For Sunscreens, In Break From Rivals

FDA Considers Capping SPF Values At 50+ Despite Efficacy Data

FDA might cap sun-protection factors at 50 or 50+ so as not to mislead consumers about the clinical benefit of sunscreens with higher SPF values, according to a proposed rule.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS017771

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel